Latest Australian Taxation News

Otto Energy has received a draft ATO Class Ruling confirming part of its $40 million capital return will be treated as a dividend, with the remainder as a return of capital. The final ruling and payment are expected in June 2025.

Top Shelf International Holdings has completed the sale of its Campbellfield production assets for $8 million, fully settling its ATO excise liability and advancing its financial restructuring.

Abacus Storage King has turned down a $1.47 per security acquisition proposal from a consortium, arguing the offer undervalues the company and carries significant tax-related risks.

Northern Star Resources has completed its acquisition of De Grey Mining through a scheme of arrangement, issuing new shares to De Grey shareholders and initiating De Grey’s imminent ASX delisting.

Wellard Limited has secured a final ATO Class Ruling confirming its 2 cents-per-share return of capital is not a dividend, clarifying tax treatment for shareholders following the sale of its MV Ocean Ute vessel.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Oldfields Holdings Limited reports solid progress in Q3 FY2025, driven by strategic transformation, debt reduction, and a robust sales pipeline supporting a positive outlook for the second half of the year.

AdNeo Limited reports a positive operating cash flow for Q3 FY25, driven by a 60% surge in customer receipts and cost savings exceeding targets. Strategic SaaS contracts and platform upgrades underpin its growth trajectory.

Cadoux Limited has made significant progress in its High Purity Alumina and Minhub rare earth projects during Q1 2025, advancing engineering studies, securing key contracts, and strengthening ESG initiatives while preparing for commercialisation.

Indiana Resources reports significant high-grade gold assay results extending the Minos Southwest Zone and deepening mineralisation, alongside a strong cash position and corporate developments including a proposed capital return.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

N1 Holdings Limited reported a solid FY25 year-to-date profit with revenue growth driven by its SME lending business, while successfully reducing funding costs and maintaining disciplined operations amid ongoing market volatility.